LONGER-TERM USE OF THE THROMBOPOIETIN-MIMETIC PEPTIBODY ROMIPLOSTIM IN CHILDREN WITH CHRONIC/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Nugent, Diane [1 ]
Bussel, James [1 ]
Buchanan, George [1 ]
Stine, Kimo [1 ]
Kalpatthi, Ramasubramanian [1 ]
Nie, Kun [1 ]
Eisen, Melissa [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
PEDIATRIC BLOOD & CANCER | 2011年 / 56卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：916 / 916
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
    Saleh, Mansoor N.
    Bussel, James B.
    Cheng, Gregory
    Meyer, Oliver
    Bailey, Christine K.
    Arning, Michael
    Brainsky, Andres
    [J]. BLOOD, 2013, 121 (03) : 537 - 545
  • [32] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Shirasugi, Yukari
    Ando, Kiyoshi
    Miyazaki, Koji
    Tomiyama, Yoshiaki
    Iwato, Koji
    Okamoto, Shinichiro
    Kurokawa, Mineo
    Kirito, Keita
    Hashino, Satoshi
    Ninomiya, Haruhiko
    Mori, Shinichiro
    Yonemura, Yuji
    Usuki, Kensuke
    Wei, Helen
    Lizambri, Richard
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (06) : 652 - 659
  • [33] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Yukari Shirasugi
    Kiyoshi Ando
    Koji Miyazaki
    Yoshiaki Tomiyama
    Koji Iwato
    Shinichiro Okamoto
    Mineo Kurokawa
    Keita Kirito
    Satoshi Hashino
    Haruhiko Ninomiya
    Shinichiro Mori
    Yuji Yonemura
    Kensuke Usuki
    Helen Wei
    Richard Lizambri
    [J]. International Journal of Hematology, 2012, 95 : 652 - 659
  • [34] Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label
    Kuter, Davrt J.
    Bussel, James B.
    Newland, Adrian
    de Wolf, Joost T. M.
    Guthrie, Troy
    Wasser, Jeffrey
    Gehl, Lara
    Nie, Kun
    Berger, Dietmar
    [J]. BLOOD, 2008, 112 (11) : 154 - 154
  • [35] Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim Analysis Of The 1-and 2-Year Romiplostim Cohorts
    Janssens, Ann
    Rodeghiero, Francesco
    Anderson, David
    Chong, Beng
    Boda, Zoltan
    Pabinger, Ingrid
    Cervinek, Libor
    Wang, Xuena
    [J]. BLOOD, 2013, 122 (21)
  • [36] Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment naive patients is consistent with the overall population in the ALITHIOS open-label extension study
    Ashgari, Rozhin
    Gaertner, Jutta
    Hauser, Stephen
    Bar-Or, Amit
    Montalban, Xavier
    Cohen, Jeffrey
    Robertson, Derrick
    Cross, Anne
    Hersh, Carrie
    Deiva, Kumaran
    Goeri, Karlsson
    Das Gupta, Ayan
    Zielman, Ronald
    Ansari, Soudeh
    Kieseier, Bernd
    Kappos, Ludwig
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP33 - NP34
  • [37] Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment naive patients is consistent with the overall population in the ALITHIOS open-label extension study
    Gaertner, J.
    Hauser, S. L.
    Bar-Or, A.
    Montalban, X.
    Cohen, J. A.
    Robertson, D.
    Cross, A. H.
    Hersh, C. M.
    Deiva, K.
    Goeril, K.
    Gupta, A. D.
    Zielman, R.
    Ansari, S.
    Kieseier, B.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 167 - 168
  • [38] Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study
    Mei, Heng
    Liu, Xiaofan
    Li, Yan
    Zhou, Hu
    Feng, Ying
    Gao, Guangxun
    Cheng, Peng
    Huang, Ruibin
    Yang, Linhua
    Hu, Jianda
    Hou, Ming
    Yao, Yazhou
    Liu, Li
    Wang, Yi
    Wu, Depei
    Zhang, Liansheng
    Zheng, Changcheng
    Shen, Xuliang
    Hu, Qi
    Liu, Jing
    Jin, Jie
    Luo, Jianmin
    Zeng, Yun
    Gao, Sujun
    Zhang, Xiaohui
    Zhou, Xin
    Shi, Qingzhi
    Xia, Ruixiang
    Xie, Xiaobao
    Jiang, Zhongxing
    Gao, Li
    Bai, Yuansong
    Xiong, Junye
    Li, Runzi
    Zou, Jianjun
    Niu, Ting
    Yang, Renchi
    Hu, Yu
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (03) : 716 - 728
  • [39] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [40] Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study
    Shinya Katsutani
    Yoshiaki Tomiyama
    Akiro Kimura
    Yoshitaka Miyakawa
    Shinichiro Okamoto
    Yasushi Okoshi
    Haruhiko Ninomiya
    Hiroshi Kosugi
    Kazuyoshi Ishii
    Yasuo Ikeda
    Toshihiro Hattori
    Koichi Katsura
    Yuzuru Kanakura
    [J]. International Journal of Hematology, 2013, 98 : 323 - 330
12345